Relay Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing operational and financial information for the third quarter.
Key Highlights
- Share count: As of October 30, 2026, Relay Therapeutics had 220,959,470 shares of common stock, $0.001 par value per share, outstanding.
- Filer classification: The company is classified as a large accelerated filer under Rule 12b-2 of the Exchange Act.
- No approved products: According to the filing, the company "has no products approved for commercial sale and has not generated any revenue from product sales."
- Continued losses: The company disclosed that it "has incurred significant operating losses since our inception and anticipates that we will incur continued losses for the foreseeable future."
- Additional funding needed: The filing states the company "will need to raise substantial additional funding" and that inability to do so could force delays, reductions, or elimination of product development programs.
- Reporting period: The quarterly report covers the period ended September 30, 2026.
Relay Therapeutics Q3 2026: Share Count, Filer Status, and Business Disclosures
Relay Therapeutics, Inc. (NASDAQ:RLAY), a biopharmaceutical company incorporated in Delaware and headquartered at 60 Hampshire Street, Cambridge, MA 02139, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing carries Commission File Number 001-39385 and was submitted with an outstanding share count of 220,959,470 shares of common stock as of October 30, 2026.
The company disclosed that it is classified as a large accelerated filer and confirmed it is not a shell company. According to the filing, Relay Therapeutics "is a biopharmaceutical company with a limited operating history" that has not yet brought any product to commercial approval. The company stated it has "incurred significant operating losses since our inception" and expects losses to continue. No revenue from product sales has been generated, according to the filing.
The filing's summary of material risks describes a range of challenges the company characterizes as associated with its business. These include the possibility that clinical trials may not replicate earlier positive data, that enrollment delays could impede regulatory approvals, and that the company faces "substantial competition." The filing also discloses reliance on third parties to conduct clinical trials and notes that failure of those parties to meet their obligations could harm the business. The company further disclosed that it "will need to raise substantial additional funding," warning that an inability to secure capital "would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts." The filing notes that forward-looking statements contained in the report are subject to the company's cautionary language and involve "known and unknown risks, uncertainties, and other factors."
What Was Disclosed
Relay Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, reporting 220,959,470 shares outstanding, large accelerated filer status, no approved products, continued operating losses, and an ongoing need for additional capital funding.



Please wait processing your request...